Home▸Alzheimer's Early Detection Blood Biomarker▸Alzheimer's Prevention Trial Biomarker Enrollment Simulator

🩸 Alzheimer's Prevention Trial Biomarker Enrollment Simulator

This simulator models the enrollment process for participants in preventive trials based on biomarker criteria.

Alzheimer's Early Detection Blood Biomarker2DModerate60 FPS
Alzheimer's Prevention Trial Biomarker Enrollment Simulator ↗ Open standalone

Asymptomatic Biomarker-Positive Population

Preclinical Alzheimer's biomarker-positive adults form the trial's target pool, placeholder.

  • 60–80 yrs: Target age range (Placeholder eligibility range)
  • Normal / unimpaired: Cognitive status (Placeholder inclusion note)
  • ~20–30%: Biomarker prevalence (Placeholder population estimate)
  • Registries & cohorts: Recruitment source (Placeholder sourcing note)

Defining the preclinical target population

Placeholder: rationale for enrolling asymptomatic biomarker-positive adults.

Blood Biomarker Pre-Screening Funnel

A blood-based assay filters the population before costlier confirmatory testing, placeholder.

  • Plasma p-tau / Aβ: Assay type (Placeholder assay note)
  • ~20%: Pre-screen positivity (Placeholder rate estimate)
  • Low relative to PET: Cost per test (Placeholder cost note)
  • Days: Turnaround (Placeholder turnaround estimate)

Blood test as a funnel narrowing step

Placeholder: blood biomarker pre-screening reduces need for confirmatory scans.

Confirmatory PET/CSF Testing

Amyloid PET or CSF testing confirms pre-screen-positive candidates, placeholder.

  • PET or CSF: Confirmation method (Placeholder method note)
  • ~60–70%: Confirmatory positivity (Placeholder concordance figure)
  • High relative to blood test: Cost (Placeholder cost note)
  • Moderate–high: Participant burden (Placeholder burden note)

Confirmatory testing accuracy and burden

Placeholder: PET/CSF confirmatory step and its accuracy trade-offs.

Trial Enrollment Eligibility Criteria

Confirmed-positive candidates are checked against remaining eligibility criteria, placeholder.

  • Normal range scores: Cognitive criteria (Placeholder criteria note)
  • Defined exclusions: Comorbidity limits (Placeholder exclusion note)
  • Informed consent: Consent process (Placeholder consent note)
  • ~1 in 15 screened: Final enroll rate (Placeholder funnel figure)

Final eligibility gate before randomization

Placeholder: eligibility criteria applied before final randomization.

Prevention Trial Cognitive Endpoint Tracking

Enrolled participants are followed on cognitive and biomarker endpoints, placeholder.

  • Cognitive composite: Primary endpoint (Placeholder endpoint note)
  • Multi-year: Follow-up duration (Placeholder duration estimate)
  • Biomarker trajectories: Secondary endpoints (Placeholder secondary note)
  • Periodic assessments: Visit cadence (Placeholder cadence note)

Tracking cognitive trajectories over time

Placeholder: long-term cognitive endpoint tracking design in prevention trials.

Placeholder key insight: early biomarker enrollment enables prevention-focused endpoints.
⚙ Under the hood

This simulator models the enrollment process for participants in preventive trials based on biomarker criteria.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)